Michel Detheux
CIK: 0001816196
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (34 total)
- Jun 11, 2026VOR
Vor Biopharma Inc.
Award(A)DirectStock option (right to buy)
57.2K shares- - Aug 29, 2025ITOS
iTeos Therapeutics, Inc.
Tender Offer(U)Indirect94K shares- - Aug 29, 2025ITOS
iTeos Therapeutics, Inc.
Tender Offer(U)Direct153.9K shares- - Aug 29, 2025ITOS
iTeos Therapeutics, Inc.
Disposition(D)DirectStock Option (Right to Buy)
14.2K shares- - Aug 29, 2025ITOS
iTeos Therapeutics, Inc.
Disposition(D)DirectStock Option (Right to Buy)
444.8K shares- - Aug 29, 2025ITOS
iTeos Therapeutics, Inc.
Disposition(D)DirectStock Option (Right to Buy)
94.3K shares- - Aug 29, 2025ITOS
iTeos Therapeutics, Inc.
Disposition(D)DirectStock Option (Right to Buy)
50.1K shares- - Aug 29, 2025ITOS
iTeos Therapeutics, Inc.
Disposition(D)DirectStock Option (Right to Buy)
17.5K shares- - Aug 29, 2025ITOS
iTeos Therapeutics, Inc.
Disposition(D)IndirectStock Option (Right to Buy)
185K shares- - Aug 29, 2025ITOS
iTeos Therapeutics, Inc.
Disposition(D)IndirectStock Option (Right to Buy)
52.7K shares- - Jul 16, 2025VOR
Vor Biopharma Inc.
Award(A)DirectStock Option (right to buy)
60K shares- - Jun 10, 2025ITOS
iTeos Therapeutics, Inc.
Exercise(M)Indirect94K shares at avg. $4.30$404K - Jun 10, 2025ITOS
iTeos Therapeutics, Inc.
Exercise(M)Direct18K shares at avg. $4.30$77K - Jun 10, 2025ITOS
iTeos Therapeutics, Inc.
Exercise(M)Direct8.4K shares at avg. $4.30$36K - Jun 10, 2025ITOS
iTeos Therapeutics, Inc.
Sale(S)Direct8.4K shares at avg. $10.02$84K - Jun 10, 2025ITOS
iTeos Therapeutics, Inc.
Exercise(M)Indirect43.9K shares at avg. $4.30$189K - Jun 10, 2025ITOS
iTeos Therapeutics, Inc.
Sale(S)Indirect43.9K shares at avg. $10.02$440K - Jun 9, 2025ITOS
iTeos Therapeutics, Inc.
Exercise(M)Direct8.4K shares at avg. $4.30$36K - Jun 9, 2025ITOS
iTeos Therapeutics, Inc.
Exercise(M)Indirect43.9K shares at avg. $4.30$189K - Jun 9, 2025ITOS
iTeos Therapeutics, Inc.
Sale(S)Direct8.4K shares at avg. $10.03$84K - Jun 9, 2025ITOS
iTeos Therapeutics, Inc.
Sale(S)Indirect43.9K shares at avg. $10.03$440K - Jun 6, 2025ITOS
iTeos Therapeutics, Inc.
Sale(S)Direct8.4K shares at avg. $10.21$86K - Jun 6, 2025ITOS
iTeos Therapeutics, Inc.
Exercise(M)Indirect43.9K shares at avg. $4.30$189K - Jun 6, 2025ITOS
iTeos Therapeutics, Inc.
Sale(S)Indirect43.9K shares at avg. $10.21$448K - Jun 6, 2025ITOS
iTeos Therapeutics, Inc.
Exercise(M)Direct8.4K shares at avg. $4.30$36K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jun 11, 2026 |  VOR Vor Biopharma Inc. | Award(A) Stock option (right to buy) | 57,162 | - | - | Direct |
| Aug 29, 2025 |  ITOS iTeos Therapeutics, Inc. | Tender Offer(U) | 94,027 | - | - | Indirect |
| Aug 29, 2025 | ITOS iTeos Therapeutics, Inc. | Tender Offer(U) | 153,903 | - | - | Direct |
| Aug 29, 2025 | ITOS iTeos Therapeutics, Inc. | Disposition(D) Stock Option (Right to Buy) | 14,185 | - | - | Direct |
| Aug 29, 2025 | ITOS iTeos Therapeutics, Inc. | Disposition(D) Stock Option (Right to Buy) | 444,815 | - | - | Direct |
| Aug 29, 2025 | ITOS iTeos Therapeutics, Inc. | Disposition(D) Stock Option (Right to Buy) | 94,336 | - | - | Direct |
| Aug 29, 2025 | ITOS iTeos Therapeutics, Inc. | Disposition(D) Stock Option (Right to Buy) | 50,128 | - | - | Direct |
| Aug 29, 2025 | ITOS iTeos Therapeutics, Inc. | Disposition(D) Stock Option (Right to Buy) | 17,544 | - | - | Direct |
| Aug 29, 2025 | ITOS iTeos Therapeutics, Inc. | Disposition(D) Stock Option (Right to Buy) | 185,000 | - | - | Indirect |
| Aug 29, 2025 | ITOS iTeos Therapeutics, Inc. | Disposition(D) Stock Option (Right to Buy) | 52,700 | - | - | Indirect |
| Jul 16, 2025 | VOR Vor Biopharma Inc. | Award(A) Stock Option (right to buy) | 60,000 | - | - | Direct |
| Jun 10, 2025 | ITOS iTeos Therapeutics, Inc. | Exercise(M) | 94,027 | $4.30 | $404,316 | Indirect |
| Jun 10, 2025 | ITOS iTeos Therapeutics, Inc. | Exercise(M) | 18,000 | $4.30 | $77,400 | Direct |
| Jun 10, 2025 | ITOS iTeos Therapeutics, Inc. | Exercise(M) | 8,400 | $4.30 | $36,120 | Direct |
| Jun 10, 2025 | ITOS iTeos Therapeutics, Inc. | Sale(S) | 8,400 | $10.02 | $84,168 | Direct |
| Jun 10, 2025 | ITOS iTeos Therapeutics, Inc. | Exercise(M) | 43,883 | $4.30 | $188,697 | Indirect |
| Jun 10, 2025 | ITOS iTeos Therapeutics, Inc. | Sale(S) | 43,883 | $10.02 | $439,708 | Indirect |
| Jun 9, 2025 | ITOS iTeos Therapeutics, Inc. | Exercise(M) | 8,400 | $4.30 | $36,120 | Direct |
| Jun 9, 2025 | ITOS iTeos Therapeutics, Inc. | Exercise(M) | 43,882 | $4.30 | $188,693 | Indirect |
| Jun 9, 2025 | ITOS iTeos Therapeutics, Inc. | Sale(S) | 8,400 | $10.03 | $84,252 | Direct |
| Jun 9, 2025 | ITOS iTeos Therapeutics, Inc. | Sale(S) | 43,882 | $10.03 | $440,136 | Indirect |
| Jun 6, 2025 | ITOS iTeos Therapeutics, Inc. | Sale(S) | 8,400 | $10.21 | $85,764 | Direct |
| Jun 6, 2025 | ITOS iTeos Therapeutics, Inc. | Exercise(M) | 43,882 | $4.30 | $188,693 | Indirect |
| Jun 6, 2025 | ITOS iTeos Therapeutics, Inc. | Sale(S) | 43,882 | $10.21 | $448,035 | Indirect |
| Jun 6, 2025 | ITOS iTeos Therapeutics, Inc. | Exercise(M) | 8,400 | $4.30 | $36,120 | Direct |
1-25 of 34 transactions
About Detheux Michel
Detheux Michel (SEC CIK 0001816196) files insider reports with the SEC as Director of Vor Biopharma Inc. (VOR) and Chief Executive Officer of iTeos Therapeutics, Inc. (ITOS).
Signal8 holds 7 ownership filings by Detheux Michel (1 Form 3, 6 Form 4), filed between Mar 11, 2025 and Jun 12, 2026. Those filings report 34 transactions, from Mar 7, 2025 to Jun 11, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Detheux Michel's filings is in BOSTON, MA.
Recent filings by Detheux Michel
- Jun 11, 2026: Grant or award of VOR derivative securities (Form 4, code A).
- Aug 29, 2025: Tender of shares transactions of ITOS shares (2 lines, Form 4, code U).
- Aug 29, 2025: Disposition to issuer transactions of ITOS derivative securities (7 lines, Form 4, code D).
- Jul 16, 2025: Grant or award of VOR derivative securities (Form 4, code A).
- Jun 10, 2025: Option exercises of ITOS shares (3 lines, Form 4, code M).
Other insiders filing for Vor Biopharma Inc. (VOR)
- RA CAPITAL MANAGEMENT, L.P., 10% Owner
- ZACCARDELLI DAVID, Director
- Namouni Fouad, Director
- Joustra Wouter, Director
- Kalir Erez, Director
- Cumbo Alexander, Director